AMRI Announces Five-Year Extension of API Supply Agreement with Shire
News Oct 23, 2012
AMRI has announced that it has entered into a multi-year supply agreement for an undisclosed product with Shire US Manufacturing Inc., whose parent company, Shire plc, is a global company that focuses its business on behavioral health, gastro intestinal diseases, rare diseases and regenerative medicine.
The agreement extends a previously existing agreement between the two companies. The terms of the agreement are confidential.
“We are pleased to extend this agreement with Shire,” said Thomas E. D’Ambra, Ph.D., Chairman, President and Chief Executive Officer of AMRI.
D’Ambra continued, “Our partnership lays the groundwork for AMRI to be considered by Shire for future development and manufacturing opportunities.”
Ingestible Drug-Delivery Materials May Improve Patient Treatment ComplianceNews
Hydrogel-based capsules could expand and reside in the GI tract for days, slowly releasing medication.READ MORE
Researchers Develop New Method to Generate Human AntibodiesNews
Researchers hope their approach will help researchers rapidly generate therapeutic antibodies for the treatment of infectious diseases and other conditions such as cancer.READ MORE
Large-Scale Production of Living Brain Cells Enables Entirely New ResearchNews
After performing a biopsy on the patient, the skin cells are transformed into brain cells that effectively imitate the disease and the age of the patient.READ MORE
Comments | 0 ADD COMMENT
8th International Symposium on Recent Advances in Food Analysis (RAFA 2017)
Nov 07 - Nov 10, 2017
6th Edition of International Conference on Pharmacognosy and Medicinal Plants
Apr 16 - Apr 17, 2018
International Conference and Exhibition on Nanomedicine and Nanotechnology
Nov 23 - Nov 24, 2017